Trial Profile
Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Apr 2020
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacokinetics; Therapeutic Use
- 09 Apr 2020 Results published in the Bone Marrow Transplantation
- 02 Mar 2020 Status changed from completed to discontinued.
- 19 Mar 2019 Status changed from recruiting to completed.